Newer antiarrhythmic drugs in children
Identifieur interne : 003125 ( Main/Corpus ); précédent : 003124; suivant : 003126Newer antiarrhythmic drugs in children
Auteurs : Jeffrey P. Moak ; Richard T. Smith ; Arthur Garson Jr.Source :
- American Heart Journal [ 0002-8703 ] ; 1986.
Abstract
Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. 26 Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.
Url:
DOI: 10.1016/0002-8703(87)90027-5
Links to Exploration step
ISTEX:F7AA86764575DDC505DDB4AEE92D41ED41DB040ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Newer antiarrhythmic drugs in children</title><author><name sortKey="Moak, Jeffrey P" sort="Moak, Jeffrey P" uniqKey="Moak J" first="Jeffrey P." last="Moak">Jeffrey P. Moak</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Richard T" sort="Smith, Richard T" uniqKey="Smith R" first="Richard T." last="Smith">Richard T. Smith</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Garson Jr, Arthur" sort="Garson Jr, Arthur" uniqKey="Garson Jr A" first="Arthur" last="Garson Jr.">Arthur Garson Jr.</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F7AA86764575DDC505DDB4AEE92D41ED41DB040E</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1016/0002-8703(87)90027-5</idno><idno type="url">https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003125</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Newer antiarrhythmic drugs in children</title><author><name sortKey="Moak, Jeffrey P" sort="Moak, Jeffrey P" uniqKey="Moak J" first="Jeffrey P." last="Moak">Jeffrey P. Moak</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Smith, Richard T" sort="Smith, Richard T" uniqKey="Smith R" first="Richard T." last="Smith">Richard T. Smith</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Garson Jr, Arthur" sort="Garson Jr, Arthur" uniqKey="Garson Jr A" first="Arthur" last="Garson Jr.">Arthur Garson Jr.</name><affiliation><mods:affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="ISSN">0002-8703</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1986">1986</date><biblScope unit="volume">113</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="179">179</biblScope><biblScope unit="page" to="185">185</biblScope></imprint><idno type="ISSN">0002-8703</idno></series><idno type="istex">F7AA86764575DDC505DDB4AEE92D41ED41DB040E</idno><idno type="DOI">10.1016/0002-8703(87)90027-5</idno><idno type="PII">0002-8703(87)90027-5</idno><idno type="ArticleID">87900275</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8703</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. 26 Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Jeffrey P. Moak M.D.</name><affiliations><json:string>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Richard T. Smith M.D.</name><affiliations><json:string>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Arthur Garson, Jr. M.D.</name><affiliations><json:string>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Progress in cardiology</value></json:item></subject><articleId><json:string>87900275</json:string></articleId><language><json:string>eng</json:string></language><abstract>Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. 26 Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.</abstract><qualityIndicators><score>6.606</score><pdfVersion>1.3</pdfVersion><pdfPageSize>545 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1974</abstractCharCount><pdfWordCount>3606</pdfWordCount><pdfCharCount>25380</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>269</abstractWordCount></qualityIndicators><title>Newer antiarrhythmic drugs in children</title><pii><json:string>0002-8703(87)90027-5</json:string></pii><genre><json:string>research-article</json:string></genre><host><volume>113</volume><pii><json:string>S0002-8703(00)X0550-9</json:string></pii><pages><last>185</last><first>179</first></pages><issn><json:string>0002-8703</json:string></issn><issue>1</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>American Heart Journal</title><publicationDate>1987</publicationDate></host><publicationDate>1986</publicationDate><copyrightDate>1987</copyrightDate><doi><json:string>10.1016/0002-8703(87)90027-5</json:string></doi><id>F7AA86764575DDC505DDB4AEE92D41ED41DB040E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Newer antiarrhythmic drugs in children</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1987</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Newer antiarrhythmic drugs in children</title><author><persName><forename type="first">Jeffrey P.</forename><surname>Moak</surname></persName><roleName type="degree">M.D.</roleName><note type="biography">Reprint requests: Jeffrey P. Moak, M.D., Texas Children's Hospital, Division of Pediatric Cardiology, 6621 Fannin, Houston, TX 77030.</note><affiliation>Reprint requests: Jeffrey P. Moak, M.D., Texas Children's Hospital, Division of Pediatric Cardiology, 6621 Fannin, Houston, TX 77030.</affiliation><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Richard T.</forename><surname>Smith</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Arthur</forename><surname>Garson, Jr.</surname></persName><roleName type="degree">M.D.</roleName><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation></author></analytic><monogr><title level="j">American Heart Journal</title><title level="j" type="abbrev">YMHJ</title><idno type="pISSN">0002-8703</idno><idno type="PII">S0002-8703(00)X0550-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1986"></date><biblScope unit="volume">113</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="179">179</biblScope><biblScope unit="page" to="185">185</biblScope></imprint></monogr><idno type="istex">F7AA86764575DDC505DDB4AEE92D41ED41DB040E</idno><idno type="DOI">10.1016/0002-8703(87)90027-5</idno><idno type="PII">0002-8703(87)90027-5</idno><idno type="ArticleID">87900275</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1987</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. 26 Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.</p></abstract><textClass><keywords scheme="keyword"><list><head>Article category</head><item><term>Progress in cardiology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1986-07-01">Registration</change><change when="1986">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>YMHJ</jid><aid>87900275</aid><ce:pii>0002-8703(87)90027-5</ce:pii><ce:doi>10.1016/0002-8703(87)90027-5</ce:doi><ce:copyright type="unknown" year="1987"></ce:copyright><ce:doctopics><ce:doctopic><ce:text>Progress in cardiology</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:title>Newer antiarrhythmic drugs in children</ce:title><ce:author-group><ce:author><ce:given-name>Jeffrey P.</ce:given-name><ce:surname>Moak</ce:surname><ce:degrees>M.D.</ce:degrees><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Richard T.</ce:given-name><ce:surname>Smith</ce:surname><ce:degrees>M.D.</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Arthur</ce:given-name><ce:surname>Garson</ce:surname><ce:suffix>Jr.</ce:suffix><ce:degrees>M.D.</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Texas Children's Hospital Houston, Texas, USA.</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Reprint requests: Jeffrey P. Moak, M.D., Texas Children's Hospital, Division of Pediatric Cardiology, 6621 Fannin, Houston, TX 77030.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="20" month="5" year="1986"></ce:date-received><ce:date-accepted day="1" month="7" year="1986"></ce:date-accepted><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. <ce:sup loc="pre">26</ce:sup> Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.</ce:simple-para><ce:simple-para view="all" id="simple-para.0015">Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Newer antiarrhythmic drugs in children</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Newer antiarrhythmic drugs in children</title></titleInfo><name type="personal"><namePart type="given">Jeffrey P.</namePart><namePart type="family">Moak</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation><description>Reprint requests: Jeffrey P. Moak, M.D., Texas Children's Hospital, Division of Pediatric Cardiology, 6621 Fannin, Houston, TX 77030.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard T.</namePart><namePart type="family">Smith</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arthur</namePart><namePart type="family">Garson, Jr.</namePart><namePart type="termsOfAddress">M.D.</namePart><affiliation>Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1986</dateIssued><dateValid encoding="w3cdtf">1986-07-01</dateValid><copyrightDate encoding="w3cdtf">1987</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Our experience with the use of five new antiarrhythmic drugs for treating life-threatening arrhythmias in children will be briefly reviewed. Prevention of recurrent episodes of atrial flutter with digoxin and local anesthetic antiarrhythmic drugs often is only moderately successful, benefiting 65% of patients. 26 Amiodarone is particularly useful for those patients who cannot be controlled on this regimen. We caution that the heart rate be monitored carefully when therapy with amiodarone is initiated in patients likely to have sick sinus syndrome. We have found mexiletine useful for controlling significant ventricular arrhythmias in patients with congenital heart disease. Likewise, 79% (11 of 14) of patients with ventricular tachycardia treated with amiodarone were well controlled. However, the range of disease categories (congenital heart disease, myocarditis, cardiomyopathy) in which amiodarone is effective is much broader than for mexiletine. Although other investigators have used amiodarone successfully for controlling supraventricular tachycardia in the Wolff-Parkinson-White syndrome or secondary to concealed accessory AV connections, we recommend surgical ablation.Propafenone has significantly improved our ability to control postoperative JET. Although JET is self-limited in duration and spontaneously remits, it frequently produces life-threatening hemodynamic compromise in the postoperative setting. Propafenone slows the ventricular rate into a range in which AV sequential pacing may be instituted. Generally, after 24 to 72 hours, the patient may be quickly weaned from propafenone. Chronic incessant supraventricular tachycardia (SVT) is frequently associated with a dilated cardiomyopathy. The two most common mechanisms of incessant SVT are PJRT and AET. We have found encainide and ethmozine extremely effective in suppressing tachycardia episodes in PJRT and AET, respectively. Medical therapy has been associated with few side effects.</abstract><subject><genre>Article category</genre><topic>Progress in cardiology</topic></subject><relatedItem type="host"><titleInfo><title>American Heart Journal</title></titleInfo><titleInfo type="abbreviated"><title>YMHJ</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">198701</dateIssued></originInfo><identifier type="ISSN">0002-8703</identifier><identifier type="PII">S0002-8703(00)X0550-9</identifier><part><date>198701</date><detail type="volume"><number>113</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue pages"><start>A4</start><end>A26</end></extent><extent unit="issue pages"><start>A40</start></extent><extent unit="issue pages"><start>A48</start><end>A54</end></extent><extent unit="issue pages"><start>A55</start><end>A58</end></extent><extent unit="issue pages"><start>1</start><end>226</end></extent><extent unit="pages"><start>179</start><end>185</end></extent></part></relatedItem><identifier type="istex">F7AA86764575DDC505DDB4AEE92D41ED41DB040E</identifier><identifier type="DOI">10.1016/0002-8703(87)90027-5</identifier><identifier type="PII">0002-8703(87)90027-5</identifier><identifier type="ArticleID">87900275</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/F7AA86764575DDC505DDB4AEE92D41ED41DB040E/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct><monogr></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ventricular arrhythmias and sudden death in children</title><author><persName><forename type="middle">A</forename><surname>Garson</surname></persName></author><author><persName><forename type="middle">Ts</forename><surname>Smith</surname></persName></author><author><persName><surname>Moak</surname></persName></author><author><persName><forename type="first">Ross</forename><forename type="middle">Ba</forename><surname>Jp</surname></persName></author><author><persName><surname>Mcnamara</surname></persName></author></analytic><monogr><title level="j">J Am Coll Cardiol</title><imprint><biblScope unit="volume">6</biblScope><biblScope unit="page" from="130" to="133"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Tachycardia induced cardiomyopathy: A revers-ible form of left ventricular dvsfunction Amiodarone: Historical development and pharma-cologic profile</title><author><persName><surname>Packer Dg</surname></persName></author><author><persName><surname>Bardy</surname></persName></author><author><persName><surname>Gh</surname></persName></author><author><persName><forename type="middle">Jj</forename><surname>Gallagher</surname></persName></author><author><persName><surname>Worley</surname></persName></author><author><persName><surname>Sj</surname></persName></author><author><persName><surname>Smith</surname></persName></author><author><persName><surname>Ms</surname></persName></author><author><persName><surname>German</surname></persName></author><author><persName><surname>Ld</surname></persName></author></analytic><monogr><title level="j">Am J Co11 Cardiol AM HEART J</title><editor>521. Singh BN</editor><imprint><biblScope unit="volume">3106</biblScope><biblScope unit="page" from="788" to="797"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Amiodarone blocks inactivated cardiac sodium cha&els</title><author><persName><forename type="first">Jw</forename><surname>Mason</surname></persName></author><author><persName><forename type="first">Lm</forename><surname>Hondeahem</surname></persName></author><author><persName><surname>Katzune</surname></persName></author><author><persName><surname>Bg</surname></persName></author></analytic><monogr><title level="j">Pflugers Arch</title><imprint><biblScope unit="volume">396</biblScope><biblScope unit="page" from="79" to="81"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effect of amiodarone on conduction and refracto-riness of the His-Purkinje system in the human heart</title><author><persName><forename type="middle">M</forename><surname>Shenasa</surname></persName></author><author><persName><forename type="first">Mahmud</forename><forename type="middle">S R</forename><surname>Denker</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Lehmann</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Estrada</surname></persName></author><author><persName><surname>Akhtar</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">4</biblScope><biblScope unit="page" from="105" to="110"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">Kaldis LC. Hittner HM: Amiodarone treatment of critical 'arrhythmias in children and young adults. J Am Co11 Cardiol</title><author><persName><forename type="middle">A</forename><surname>Garson</surname></persName></author><author><persName><forename type="middle">Pc</forename><surname>Gillette</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Mcvey</surname></persName></author><author><persName><surname>Hesslein</surname></persName></author><author><persName><surname>Ps</surname></persName></author><author><persName><forename type="middle">Cj</forename><surname>Porter</surname></persName></author><author><persName><surname>Lk</surname></persName></author><imprint><date type="published" when="1984"></date><biblScope unit="page" from="749" to="755"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Relationship between amiodarone efficacy and serum drug levels in a young population Marcus F: Drug interactions with amiodarone</title><author><persName><forename type="middle">R</forename><surname>Kannan</surname></persName></author><author><persName><surname>Yabek</surname></persName></author><author><persName><surname>Sm</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Garson</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Mcvey</surname></persName></author><author><persName><surname>Singh Bn Doyle Ef</surname></persName></author><author><persName><forename type="middle">Ma</forename><surname>Engle</surname></persName></author><author><persName><forename type="middle">Wm</forename><surname>Gersony</surname></persName></author><author><persName><surname>Wj</surname></persName></author><author><persName><surname>Tamer</surname></persName></author><author><persName><surname>Ns</surname></persName></author></analytic><monogr><title level="m">Pediatric cardiology</title><meeting><address>New York</address></meeting><imprint><publisher>Springer-Verlag</publisher><date type="published" when="1983"></date><biblScope unit="page" from="924" to="929"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Amiodarone in the treatment of cardiac arrhythmias in children: One hundred thirty-five cases</title><author><persName><forename type="first">Coumel</forename><forename type="middle">P</forename><surname>Fidelle</surname></persName></author></analytic><monogr><title level="j">AM HEART J</title><imprint><biblScope unit="volume">100</biblScope><biblScope unit="page" from="1063" to="1069"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Amiodarone in control of sustained tachyarrhythmias in children with Wolff-Parkinson-White syndrome</title><author><persName><forename type="middle">E</forename><surname>Shahar</surname></persName></author><author><persName><forename type="middle">Z</forename><surname>Barzilay</surname></persName></author><author><persName><forename type="middle">M</forename><surname>Frand</surname></persName></author></analytic><monogr><title level="j">Pediatrics</title><imprint><biblScope unit="volume">72</biblScope><biblScope unit="page" from="813" to="816"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Pharmacology, electrophysiol-ogy and pharmacokinetics of mexiletine</title><author><persName><forename type="first">Wang</forename><forename type="middle">T</forename><surname>Woosley Rl</surname></persName></author><author><persName><forename type="middle">W</forename><surname>Stone</surname></persName></author><author><persName><forename type="middle">L</forename><surname>Siddoway</surname></persName></author><author><persName><forename type="middle">K</forename><surname>Thompson</surname></persName></author><author><persName><forename type="first">Cerskus</forename><forename type="middle">I</forename><surname>Duff Hj</surname></persName></author><author><persName><surname>Roden</surname></persName></author></analytic><monogr><title level="j">AM HEART J</title><imprint><biblScope unit="volume">107</biblScope><biblScope unit="page" from="1058" to="1065"></biblScope><date type="published" when="000-1"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Mexiletine: An alternative to dilantin for pediatric ventricular arrhythmias</title><author><persName><surname>Moak Jp</surname></persName></author><author><persName><surname>Gillette Pc</surname></persName></author><author><persName><surname>Garson</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">70</biblScope><biblScope unit="page" from="11" to="206"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Oral mexiletine in the treatment of refractory ventricular arrhythmias: The role of electrophysiologic techniques</title><author><persName><surname>Schoenfeld Mh</surname></persName></author><author><persName><forename type="middle">E</forename><surname>Whifford</surname></persName></author><author><persName><forename type="middle">B</forename><surname>Mcgovern</surname></persName></author><author><persName><forename type="middle">H</forename><surname>Garan</surname></persName></author><author><persName><surname>Jn</surname></persName></author></analytic><monogr><title level="j">AM HEART J</title><imprint><biblScope unit="volume">107</biblScope><biblScope unit="page" from="1071" to="1078"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Pronafenone-a new antiarrhvthmic d&g</title><author><persName><forename type="first">L</forename><surname>Seine1</surname></persName></author><author><persName><surname>Breithardt</surname></persName></author></analytic><monogr><title level="j">Eur Heart J</title><imprint><biblScope unit="volume">1</biblScope><biblScope unit="page" from="369" to="313"></biblScope><date type="published" when="1980"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects of propafenone on canine ischemic cardiac cells</title><author><persName><surname>Zeiler Rh</surname></persName></author><author><persName><surname>Gough Wb</surname></persName></author><author><persName><surname>Sherif</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="volume">54</biblScope><biblScope unit="page" from="424" to="429"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects and clinical efficacy of oral propa-fenone therapy-in patients with ventricular tachycardia</title><author><persName><forename type="first">Chilson</forename><forename type="middle">Da</forename><surname>Heger Jj</surname></persName></author><author><persName><forename type="first">Zipes</forename><forename type="middle">Dp K</forename><surname>Browne</surname></persName></author><author><persName><surname>Prystowksy</surname></persName></author><author><persName><surname>En</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page" from="1407" to="1413"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Control of postoperative junctional ectopic tachycardia with propafenone</title><author><persName><forename type="middle">A</forename><surname>Garson</surname></persName></author><author><persName><surname>Moak</surname></persName></author><author><persName><surname>Jp</surname></persName></author><author><persName><forename type="middle">Rt</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Mcvey</surname></persName></author><author><persName><surname>Norton</surname></persName></author><author><persName><surname>Jb</surname></persName></author></analytic><monogr><title level="j">J Am Coll Cardiol</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page">428</biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electrophysiologic effects of encainide (MJ 9067) on canine Purkinje fibers</title><author><persName><surname>Gibson Jk</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Somani</surname></persName></author><author><persName><surname>Bassett</surname></persName></author><author><persName><surname>Al</surname></persName></author></analytic><monogr><title level="j">Eur J Pharmacol</title><imprint><biblScope unit="volume">52</biblScope><biblScope unit="page" from="161" to="169"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Clinical electro-physiologic effects of encainide, a newly developed antiar-rhythmic agent</title><author><persName><forename type="middle">M</forename><surname>Sami</surname></persName></author><author><persName><forename type="first">Peters</forename><forename type="middle">Jw F</forename><surname>Mason</surname></persName></author><author><persName><surname>Harrison</surname></persName></author><author><persName><surname>Dc</surname></persName></author></analytic><monogr><title level="j">Am J Cardiol</title><imprint><biblScope unit="page" from="197344526" to="532"></biblScope></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Garson A: Encainide; aspecific drug for permanent junctional recipro-cating tachycardia (PJRT) in children</title><author><persName><forename type="middle">J</forename><surname>Strasburger</surname></persName></author><author><persName><forename type="middle">Rt</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">Jp</forename><surname>Moak</surname></persName></author><author><persName><surname>Mcvey</surname></persName></author></analytic><monogr><title level="j">J Am Coll Cardiol</title><imprint><biblScope unit="volume">7</biblScope><biblScope unit="page">119</biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Electro-physiologic effects of ethmoxine on canine myocardium</title><author><persName><forename type="first">Rutiy</forename><forename type="middle">R</forename><surname>Lv</surname></persName></author><author><persName><forename type="middle">V</forename><surname>Elharrar</surname></persName></author><author><persName><surname>Dp</surname></persName></author></analytic><monogr><title level="j">Cardiovasc Res</title><imprint><biblScope unit="volume">13</biblScope><biblScope unit="page" from="354" to="363"></biblScope><date type="published" when="1979"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Effects of the phenothiasine analog, EN-313, on ventricular arrhyth-mias in the dog</title><author><persName><forename type="first">Danilo</forename><forename type="middle">P Wb</forename><surname>Langan</surname></persName></author><author><persName><forename type="first">Rosen</forename><forename type="middle">Mr</forename><surname>Hoffman</surname></persName></author></analytic><monogr><title level="j">Eur J</title><imprint><biblScope unit="volume">45</biblScope><biblScope unit="page" from="127" to="139"></biblScope><date type="published" when="1977"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Rosenshtraukh LV: Ethmozine. I. Effects of intravenous &g administration on proxysmal supraventricular tachycardia in the ventricular preexcitation syndrome</title><author><persName><forename type="first">Ei</forename><surname>Chaxov</surname></persName></author><author><persName><surname>Shueushev</surname></persName></author><author><persName><surname>Kk</surname></persName></author></analytic><monogr><title level="j">AM HEART J</title><imprint><biblScope unit="volume">108</biblScope><biblScope unit="page" from="475" to="482"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Ethmozine: A promising drug for " automatic " atrial ectopic focus tachycardia</title><author><persName><forename type="first">Evans</forename><forename type="middle">V A</forename><surname>Garson</surname></persName></author><author><persName><forename type="middle">Rt</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">Jp</forename><surname>Moak</surname></persName></author><author><persName><forename type="middle">P</forename><surname>Mcvey</surname></persName></author><author><persName><surname>Dg</surname></persName></author></analytic><monogr><title level="j">Circulation</title><imprint><biblScope unit="volume">72</biblScope><biblScope unit="page" from="111" to="173"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct><analytic><title level="a" type="main">Supraventricular tachycardia due to multi-ple atrial ectopic foci: A relatively common problem</title><author><persName><forename type="middle">A</forename><surname>Garson</surname></persName></author><author><persName><forename type="middle">Rt</forename><surname>Smith</surname></persName></author><author><persName><forename type="middle">Jp</forename><surname>Moak</surname></persName></author><author><persName><forename type="middle">Da</forename><surname>Ott</surname></persName></author><author><persName><forename type="first">Evans</forename><forename type="middle">Pc Va</forename><surname>Gillette</surname></persName></author><author><persName><surname>Duncan</surname></persName></author><author><persName><surname>Pm</surname></persName></author></analytic><monogr><title level="j">J Am Co11 Cardiol</title><imprint><biblScope unit="volume">7</biblScope><biblScope unit="page">119</biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct><monogr><title level="m" type="main">Porter CJ, and the Other Investigators of the Pediatric Electrophysiology Society: Atrial flutter in the young: A collaborative study of 380 cases. J Am Co11 Cardiol</title><author><persName><forename type="middle">A M</forename><surname>Garson</surname></persName></author><author><persName><surname>Hesslein Ps</surname></persName></author><author><persName><forename type="middle">A</forename><surname>Hordof</surname></persName></author><author><persName><surname>Keane Jf</surname></persName></author><author><persName><surname>Wh</surname></persName></author><imprint><date type="published" when="1985"></date><biblScope unit="page" from="871" to="878"></biblScope></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 003125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:F7AA86764575DDC505DDB4AEE92D41ED41DB040E
|texte= Newer antiarrhythmic drugs in children
}}
| This area was generated with Dilib version V0.6.23. |  |